Product Images Rizatriptan Benzoate

The text provides a graph (Figure 1) showing the estimated probability of achieving an initial headache response within 2 hours after treatment with rizatriptan benzoate or placebo. The graph includes data from four placebo-controlled outpatient trials (Studies 1, 2, 3, and 4). The graph displays the probabilities over time and includes different treatment options: placebo, rizatriptan benzoate 5 mg, and rizatriptan benzoate 10 mg. The averages displayed on the graph are based on pooled data from these trials. The graph is a Kaplan-Meier plot, with the x-axis representing hours post-dose and the y-axis representing the probability of achieving headache response.*

Figure 2 depicts the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over a 24-hour period following the initial dose of study treatment. The data used in this analysis were obtained from pooled studies 1, 2, 3, and 4. The table within the figure provides the percentage of patients who took a second dose at different time intervals. The Kaplan-Meier plot includes patients who had a headache response at 2 hours and those who had no response to the initial dose. It should be noted that remedication within 2 hours post-dose was not allowed and patients not using additional treatments were censored at 24 hours. This analysis aims to provide valuable insights into the likelihood of patients requiring a second dose of medication for migraines.*